Fulcrum Therapeutics Q4 EPS $(0.31), Inline
Benzinga Newsdesk 8 months ago
EarningsNews
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.31) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.31) per share which met the analyst consensus estimate. This is unchanged from the same period last year.